Opinion
A look at how the gene therapy approvals may end up confusing payers, lawmakers, and the general public at a time when the industry desperately needs clarity.
Halozyme’s Enhanze drug delivery technology just won it a $105 million upfront payment from Bristol-Myers Squibb.
Kare Schultz will become Teva’s fourth CEO in a decade, and its second outsider.
Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.
Biotech has been on fire this year, with the iShare Nasdaq Biotechnology index more than doubling the gains of the S&P 500 year-to-date.
